ASSESSMENT OF REGORAFENIB, RAMUCIRUMAB AND CABOZANTINIB AS SECONDLINE THERAPY IN HEPATOCARCINOMA AND ALFA-FETOPROTEIN VALUE ≥400 NG/ML (submitted in 2019)
ASSESSMENT OF REGORAFENIB, RAMUCIRUMAB AND CABOZANTINIB AS SECONDLINE THERAPY IN HEPATOCARCINOMA AND ALFA-FETOPROTEIN VALUE ≥400 NG/ML (submitted in 2019)